The Royal Society of Medicine hosted its 13th Medical Innovations Summit on Saturday 17th September 2016. The videos from this summit can be found here which showcases the innovators we were privileged to host as part of our incredible line up of speakers.
The 14th Medical Innovations Summit is taking place on Saturday 22 April 2017, bookings are now open. As with all summits, we expect it to be a sell-out so book early to avoid disappointment.
We are very pleased to be able to announce our line-up of speakers, details of which can be found below.
There are an estimated two million hand amputees in the world. Open Bionics was co-founded by Samantha Payne to spread the use of affordable, highly functional prosthetics around the globe, by combining open source developer software with low-cost 3D printing techniques. Recently the company has partnered with Disney and Marvel to turn children with limb differences into superheroes with robotic hands.
More than two billion people lack adequate access to essential medical products, often due to challenging terrain and gaps in infrastructure. Because of this, over 2.9 million children under the age of five die every year and up to 150,000 pregnancy-related deaths could be avoided each year if mothers had reliable access to safe blood. Max Alexander-Wall and Keller Rinaudo will speak about ‘Zipline’ a small robot airplane designed to carry vaccines, medicine, or blood. Max will be presenting in London and Keller will be speaking about their trials in Rwanda via video-link from Africa.
Gordon Sanghera has a grand ambition: to build a new science-based company under British ownership that commands a large global market. He is already on the way with Oxford Nanopore Technologies, the gene-reading company he has led since its foundation. The aim is to become the world’s leading producer of equipment to decode the DNA of any organism, from people to viruses, in applications from medical diagnosis to food safety. In December the company raised £100 million in new funding.
Professor Eleanor Stride is an expert in drug delivery systems engineering and biomedical ultrasonics. She works at the Institute of Biomedical Engineering at the University of Oxford and last year appeared in the Daily Telegraph’s list of the Top 50 Women in Engineering. Her research is based on how best to develop revolutionary new methods for delivering chemotherapy drugs? Recently she conducted trials using bubbly oxygen-rich drinks to enhance the therapies for treating low-oxygen cancer.
Dr Ronald Brus is flying in from Holland just for the Summit. He founded ‘myTomorrows’ after his father developed cancer and had run out of treatment options. He started to contact big pharmaceutical companies to see if he could get access to drugs in development. ‘myTomorrows’ has raised over 10 million Euros in order to help doctors and terminally ill patients access drugs and establish a global database of unapproved medicines.
‘AI’ – Artificial intelligence is a term used in the media on an increasingly regular basis. What does it mean and how does it apply in the medical sector? Professor Jackie Hunter CBE, a board member of Benevolent AI and the CEO of BenevolentBio, has established a business based on software which sifts through vast chemical libraries, medical databases and conventionally presented scientific papers, looking for potential drug molecules.
In the USA alone, over 325,000 people suffer cardiac arrest out of hospital every year. Heat stroke is an equally challenging problem in the Middle East and other hot regions, and also causes deaths at sporting events worldwide. Dr Rowley Cottingham and Jonathan Weinberg have created CAERvest®- a radical life-saving solution to the previously unsolved problem of rapidly cooling the body after heat stroke or cardiac arrest. The first and only portable, practical and effective device of its kind. Dr Cottingham is a Consultant in Emergency Medicine, at Brighton and Sussex University Hospitals NHS Trust and Mr Weinberg is the Chief Executive of BodyChillz.
‘It wasn’t like that in my day’ is one of those comments so many older doctors and healthcare professionals state when meeting medical students. Yet many medical students and a growing number of medical educators believe the current medical curricular has barely changed in years. They also think teaching methods are anachronistic and medical students are ill-prepared to become doctors in 2017. So how can the teaching of medical education be improved? GP and Head of Undergraduate Primary Care Teaching at Imperial College, Dr Sonia Kumar will talk about some extraordinary educational programmes she has initiated and will be joined by Dr Ravi Parekh, ST4 GP Registrar and Academic Clinical Fellow from Imperial and Ms Atisha Tank a 5th year medical student.
Do you have kids or grandchildren who spend a ridiculous amount of time sitting on the sofa playing mindless video games? You might want to look a little closer at what game they are playing. ‘Sea Hero Quest’ is a game that has been played by more than 2.4 million people and contains a diagnostic test for the early signs of Alzheimer’s disease. It has become the largest dementia study in history. Our speakers are Professor Michael Hornberger, Chair of Applied Dementia Research at Norwich Medical School (UEA) and the Co-Creator of Sea Hero Quest. He will be joined by Maxwell Scott-Slade, Co-Founder and Game Design Director of Glitchers the video company behind the development of Sea Hero Quest.
Each year in the UK, 50,000 people have a stroke and up to 50% of stoke diagnosis are inaccurate. What to do? The Observer newspaper described Professor Nicholas Dale’s pioneering contribution to stroke medicine as a classic tale of scientific innovation replete with accidental discoveries, chance meetings and frustrating setbacks. In 2014 Dale began clinical trials in three hospitals, Salford, Coventry and Stoke-on-Trent using a unique biosensor. Dale will tell his story alongside Professor Christina Roffe who has been trialling the biosensor in Stoke’s acute stroke unit. The results are impressive.
Have you heard of Parachute therapy? Established by the New York Dept of Health and Mental Hygiene the Parachute programme’s approach is ‘open dialogue’ in which a team of therapists, social workers and peers, encourage patients and their families to develop their route to achieving recovery. The programme has proven its ability to reduce rates of hospitalisation and to save money. The programme is due to be trialled in London in 2017/18 and will be led by Dr Russell Razzaque, Associate Medical Director at the North East London NHS Trust. The presentation will also include a contribution by Dr Mary Olson, Assistant Professor of Psychiatry at the University of Massachusetts Medical School.
Immunotherapy is a class of treatments where the body’s immune system is activated to attack cancer. Patients with some of the most aggressive tumours have lived on for years thanks to immunotherapy innovations. In 2015 Immunocore raised over £205 million in the biggest private financing for a European life sciences company. Dr Christina Coughlin, Immunocore’s Chief Medical Officer, is flying in from the USA to provide a briefing on Immunocore’s story, challenges, trials and plans.
Imagine being told by a doctor that your child has an incurable disease. Karen Aiach, an accountant in France, found herself in exactly this situation. Her baby daughter, Ornella, was diagnosed with Sanfilippo Syndrome A, a rare neurodegenerative disease. What she did next was exceptional and extraordinary. She established her own biotech company, Lysogene which is developing gene therapy treatments for rare central nervous system diseases. Karen will speak about the progress the company has made and will be joined by Dr Michel Zerah, Professor of Neurosurgery at Necker Hôpital Enfants Malades, Paris, who has been directly involved in Lysogene’s clinical trials.
Maxine is the Co-Founder and Chair of HealthTech Women UK – a professional network which supports and promotes women to be the future leaders of medical innovation. She does this alongside a PhD in data science and dementia at the University College London. Previously, she has worked at the Royal Society, Roche, L’Oreal, DIFD, and NHS England and remains an active member of the health innovation community.